Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa

Tropical Medicine and International Health

Volumn 18, Issue 1, 2013, Pages 109-116

  Schnippel, Kathryn ^a   Rosen, Sydney ^a,b   Shearer, Kate ^a   Martinson, Neil ^a,c   Long, Lawrence ^a   Sanne, Ian ^a,b   Variava, Ebrahim ^d,e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Klerksdorp/Tshepong Hospital Complex   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Cost; Hospitalisation; Multi drug resistant; South Africa; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TERIZIDONE;

COST-BENEFIT ANALYSIS; DISEASE TREATMENT; DRUG RESISTANCE; HOSPITAL SECTOR; NUMERICAL MODEL; PUBLIC SECTOR; TUBERCULOSIS;

ADULT; ARTICLE; BUILDING; DEATH; DRUG COST; DRUG SENSITIVITY; FEMALE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; MULTIDRUG RESISTANT TUBERCULOSIS; PERSONNEL MANAGEMENT; PRACTICE GUIDELINE; SOUTH AFRICA;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT DISCHARGE; PREVALENCE; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

SOUTH AFRICA;

EID: 84871680477     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12018     Document Type: Article

References (20)

1. Brust JCM, Lygizos M, Chaiyachati K et al. (2011) Culture conversion among HIV Co-infected multidrug- resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS One 6, e15841.
2. Day C, Barron P, Massyn N, Padarath A & English R (eds) (2012) District Health Barometer 2010/11. Health Systems Trust, Durban. ISBN Number: 978-1-919839-70-7.
3. Directorate Drug- Resistant TB (2011a) Multi-Drug Resistant Tuberculosis: A Policy Framework on Decentralised and Deinstitutionalised Management for South Africa. Infection Control. Directorate Drug- Resistant TB, Pretoria.
4. Directorate Drug- Resistant TB (2011b) Management of Drug-Resistant Tuberculosis: Policy Guidelines. Health Care. Directorate Drug- Resistant TB, Pretoria.
5. Directorate Tuberculosis Control (2007) Management of Drug-resistant Tuberculosis in South Africa: Policy Guidelines. Directorate Drug- Resistant TB, Pretoria.
6. Farley JE, Ram M, Pan W et al. (2011) Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One 6, e20436.
7. Fitzpatrick C & Floyd K (2012) A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 30, 63-80.
8. Floyd K (2002) Guidelines for Cost and Cost-effectiveness Analysis of Tuberculosis Control. Guidelines for Cost and Cost-effectiveness Analysis of Tuberculosis Control. WHO, Geneva. doi: WHO/CDS/TB/2002.305a.
9. Gandhi NR, Shah NS, Andrews JR et al. (2010) HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. American Journal of Respiratory and Critical Care Medicine 181, 80-86.
10. Long L, Fox M, Sanne I & Rosen S (2010) The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 24, 915-919.
11. Meyer-Rath G, Schnippel K, Long L et al. (2012) The impact and cost of scaling up GeneXpert MTB/RIF in South Africa (ed. MP Nicol) PLoS One 7, e36966.
12. Oanda (2012) USD ZAR Average exchange rate 1 Jan 2011-31 Dec 2011. Historical Exchange Rates. http://www.oanda.com/currency/historical-rates/
13. Orenstein EW, Basu S, Shah NS et al. (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. The Lancet Infectious Diseases 9, 153-161.
14. Sinanovic E, Floyd K, Dudley L, Azevedo V, Grant R & Maher D (2003) Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa. The International Journal of Tuberculosis and Lung Disease 7, S56-S62.
15. Statistics South Africa (2012) Statistical Release: Consumer Price Index, Vol. P0141. Statistics South Africa, Pretoria.
16. Suchindran S, Brouwer ES & Van Rie A (2009) Is HIV infection a risk factor for multi-drug resistant tuberculosis? a systematic review PLoS One 4, e5561.
17. TB Control Programme (2008) South African National Tuberculosis Guidelines. South Africa National Department of Health, Pretoria.
18. WHO (2011a) Towards Universal Access to Diagnosis and Treatment of Multidrug-resistant and Extensively Drug-resistant Tuberculosis by 2015: WHO Progress Report 2011. WHO, Geneva.
19. WHO (2011b) Global Tuberculosis Control: WHO Report 2011. Tuberculosis. WHO, Geneva. doi: ISBN 978 92 4 156438 0.
20. Zignol M, Gemert WV, Falzon D et al. (2012) Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis 2007 - 2010. Bulletin of the World Health Organization 90, 111-119.